Citation Impact
Citing Papers
Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape
2017
Prognostic Utility of Molecular Factors by Age at Diagnosis of Colorectal Cancer
2015
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
2017 Standout
Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities
2022 Standout
Cancer immunotherapies targeting the PD-1 signaling pathway
2017 StandoutNobel
Exosomal microRNA miR-1246 induces cell motility and invasion through the regulation of DENND2D in oral squamous cell carcinoma
2016
European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update
2015 Standout
QuPath: Open source software for digital pathology image analysis
2017 Standout
Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial
2017
mRNA vaccines — a new era in vaccinology
2018 StandoutNobel
Precision oncology in the age of integrative genomics
2018
Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis
2014 Standout
The immune contexture in cancer prognosis and treatment
2017 Standout
Current and future perspectives of liquid biopsies in genomics-driven oncology
2018 Standout
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
2017 Standout
Active Surveillance for Low-Risk Prostate Cancer Worldwide: The PRIAS Study
2012
Genetic Susceptibility Loci, Pesticide Exposure and Prostate Cancer Risk
2013
Colorectal cancer
2019 Standout
Apoptosis in cancer: from pathogenesis to treatment
2011 Standout
Inhibiting eukaryotic transcription. Which compound to choose? How to evaluate its activity?
2011 Standout
Outsmarting androgen receptor: creative approaches for targeting aberrant androgen signaling in advanced prostate cancer
2011
The use of combinations of monoclonal antibodies in clinical oncology
2015
Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation
2018 Standout
Small-molecule Mcl-1 inhibitors: Emerging anti-tumor agents
2018
Targeting apoptosis in cancer therapy
2020 Standout
Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics
2019
Self-consumption: the interplay of autophagy and apoptosis
2014 Standout
Regulation and Function of the PD-L1 Checkpoint
2018 Standout
Urothelial carcinoma management in elderly or unfit patients
2016
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
2016 Standout
Oxidative Stress in Cancer
2020 Standout
Aspirin and colorectal cancer: the promise of precision chemoprevention
2016
PROTAC targeted protein degraders: the past is prologue
2022 Standout
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
2013 Standout
BCL-2 family isoforms in apoptosis and cancer
2019 Standout
Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2013
Colorectal Cancer Epidemiology: Incidence, Mortality, Survival, and Risk Factors
2009 Standout
Immune checkpoint inhibitors: recent progress and potential biomarkers
2018 Standout
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
2018 Standout
Epidemiology of colorectal cancer
2002
Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide
2021
Next generation predictive biomarkers for immune checkpoint inhibition
2016
A guide to cancer immunotherapy: from T cell basic science to clinical practice
2020 Standout
HER2 overexpression is associated with worse outcomes in patients with upper tract urothelial carcinoma (UTUC)
2016
Targeting the B-cell receptor signaling pathway in B lymphoid malignancies
2014
EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent—Update 2013
2013 Standout
Systemic Therapy for Metastatic Renal-Cell Carcinoma
2017
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
2016 Standout
Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
2016
Identification of Novel Oncogenic Mutations in Thyroid Cancer
2016
Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma
2015 Standout
Deacetylated sialic acids modulates immune mediated cytotoxicity via the sialic acid-Siglec pathway
2021 StandoutNobel
Circulating tumor DNA alterations in patients with metastatic castration‐resistant prostate cancer
2019
Venetoclax in Patients with Previously Treated Chronic Lymphocytic Leukemia
2017
Photothermal therapy and photoacoustic imaging via nanotheranostics in fighting cancer
2018 Standout
EDC-2: The Endocrine Society's Second Scientific Statement on Endocrine-Disrupting Chemicals
2015 Standout
Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma
2017
Enzalutamide for the Treatment of Prostate Cancer: Results and Implications of the AFFIRM Trial
2014
Bladder Cancer
2020 Standout
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Chemotherapy for advanced gastric cancer
2017 Standout
Novel agents for the treatment of chronic lymphocytic leukemia.
2010
High expression of PD-1 ligands is associated with kataegis mutational signature and APOBEC3 alterations
2017
Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia
2011
The biology , function , and biomedical applications of exosomes
2020 StandoutScience
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
2015 Standout
What Potential Does plasmonics-amplified Synergistic Immuno Photothermal Nanotherapy have for Treatment of cancer?
2017
Targeting the B-Cell Lymphoma/Leukemia 2 Family in Cancer
2012
Roles of NF-κB in Cancer and Inflammatory Diseases and Their Therapeutic Approaches
2016 Standout
Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma
2015
The VHL Tumor Suppressor Gene: Insights into Oxygen Sensing and Cancer.
2017 StandoutNobel
CTLA-4 and PD-1 Pathways
2015 Standout
Prognostic Role of PD-L1 in Malignant Solid Tumors: A Meta-Analysis
2017
Pretreatment Neutrophil-to-Lymphocyte Ratio in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Ketoconazole: Association with Outcome and Predictive Nomogram
2012
Works of Lillian Werner being referenced
Association of Prostate Cancer Risk Loci with Disease Aggressiveness and Prostate Cancer–Specific Mortality
2011
2015
Correlation of Apobec Mrna Expression with overall Survival and pd-l1 Expression in Urothelial Carcinoma
2016
Obatoclax in combination with fludarabine and rituximab is well-tolerated and shows promising clinical activity in relapsed chronic lymphocytic leukemia
2015
Imaging, procedural and clinical variables associated with tumor yield on bone biopsy in metastatic castration-resistant prostate cancer
2014
Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma
2015
A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma
2013
Secondary Hormonal Therapy in Men With Castration-Resistant Prostate Cancer
2011
Aspirin Use, 8q24 Single Nucleotide Polymorphism rs6983267, and Colorectal Cancer According to CTNNB1 Alterations
2013
MicroRNA Expression Profiling Identifies Activated B Cell Status in Chronic Lymphocytic Leukemia Cells
2011
Identification of ALK Gene Alterations in Urothelial Carcinoma
2014
Predictive factors for all-trans retinoic acid-related differentiation syndrome in patients with acute promyelocytic leukemia
2013
Somatic Copy Number Abnormalities and Mutations in PI3K/AKT/mTOR Pathway Have Prognostic Significance for Overall Survival in Platinum Treated Locally Advanced or Metastatic Urothelial Tumors
2015
A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemia
2017
Identification of a novel urothelial carcinoma (UC) biomarker of lethality.
2011
A Phase I Study of Lenalidomide in Combination with Fludarabine-Rituximab in Previously Untreated CLL/SLL.
2009
Obatoclax in Combination with Fludarabine and Rituximab (FR) Is Well-Tolerated and Shows Promising Clinical Activity in Relapsed CLL/SLL
2011
SLCO2B1andSLCO1B3May Determine Time to Progression for Patients Receiving Androgen Deprivation Therapy for Prostate Cancer
2011
Clinical outcome of patients with acute promyelocytic leukemia and FLT3 mutations
2010
Phase II Study of Androgen Synthesis Inhibition with Ketoconazole, Hydrocortisone, and Dutasteride in Asymptomatic Castration-Resistant Prostate Cancer
2009
Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor‐risk metastatic renal cell carcinoma
2015
NF-κB Pathway Mutations Modulate Cell Survival and Ibrutinib Response In Chronic Lymphocytic Leukemia
2013
Functional Somatic and Germline Variants in the NF-κB Pathway in Chronic Lymphocytic Leukemia
2012
Risk Stratification and Validation of Prostate Specific Antigen Density as Independent Predictor of Progression in Men With Low Risk Prostate Cancer During Active Surveillance
2010
PD-L1 expression in mononuclear cells and not in tumor cells, correlated with prognosis in metastatic urothelial carcinoma.
2014